PRODUCTS NOT CURRENTLY AVAILABLE FOR COMMERCIAL SALE
HeLP™ Prostate Cancer Tests
When facing the possibility of prostate cancer, two questions matter most:
Do I actually have cancer?
If I do, is it the aggressive kind that requires urgent treatment?
HeLP™ Prostate Cancer tests are designed to help patients and physicians answer both—with greater clarity, precision, and confidence from a simple blood draw.
By measuring platelet-associated protein signals linked to active tumor biology, HeLP™ provides insights that go beyond traditional PSA testing and imaging alone.
HeLP™ Detect PC
Identifies whether clinically significant prostate cancer is likely to be found on biopsy.
Helps reduce unnecessary biopsies for men whose risk is low.
Unlike PSA, which can rise for many non-cancer reasons, HeLP™ Detect PC looks for protein signatures specific to active prostate cancer biology.
HeLP™ Monitor PC
Helps identify whether prostate cancer is biologically aggressive or likely to remain indolent.
Supports better decisions about whether immediate treatment is needed or active surveillance is appropriate.
Provides greater confidence in choosing the right care for the right disease state.
Why It Matters
Together, HeLP™ prostate tests reduce uncertainty, minimize unnecessary procedures, and help guide more personalized care…so patients can move forward with clarity and confidence.
HeLP™ Breast Cancer Tests
In breast cancer care, patients and physicians often face three critical questions:
Is the lesion invasive or non-invasive?
If I carry a high-risk mutation, is disease progression beginning?
Is my treatment working—or does it need to change?
HeLP™ Breast Cancer tests are designed to provide clearer answers through a simple blood draw.
By measuring real-time biological activity rather than relying only on imaging or genetic risk, HeLP™ helps support earlier intervention and better treatment decisions.
HeLP™ Define BC
Helps distinguish whether a breast lesion—such as DCIS identified on mammography—is non-invasive or progressing toward invasive disease.
Provides clarity for treatment decisions and helps reduce unnecessary intervention when risk is low.
HeLP™ Detect Progression BC
Designed for women with elevated inherited risk, including BRCA1, BRCA2, Cowden syndrome, and Lynch syndrome.
Detects early biological signals that may indicate progression toward cancer—before structural disease becomes obvious.
Supports earlier and more proactive clinical care.
HeLP™ Monitor Therapy BC
Helps determine whether targeted therapies are working as intended.
Provides earlier insight into therapeutic response and supports faster treatment adjustments when needed.
Looking Ahead
The HeLP™ platform is also advancing in additional disease areas, including pancreatic cancer and neurodegenerative disease, expanding the potential of platelet proteomics to improve care across multiple conditions.